– Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors – TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , “Astellas”) and Poseida Therapeutics ,